Stock Events

Stock Events

Scilex Company 

$7.44
42
+$0.53+7.67% Thursday 20:00

Statistics

Day High
7.76
Day Low
6.77
52W High
34.27
52W Low
3.6
Volume
54,706
Avg. Volume
52,227
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-22.17
-14.81
-7.45
-0.09
Expected EPS
-0.3373
Actual EPS
N/A

Financials

-128.66%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
56.59MRevenue
-72.81MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SCLX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing directly with Scilex in the pain management pharmaceutical market.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in developing treatments for pain, directly overlapping with Scilex's market.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a large pharmaceutical company with a broad portfolio that includes pain management solutions, competing with Scilex's products.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, with its range of pain management drugs, competes in the same therapeutic areas as Scilex, particularly in chronic pain.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. competes with Scilex through its development and marketing of pharmaceuticals for various conditions, including pain management.
AMGEN
AMGN
Mkt Cap160.66B
Amgen, with its focus on biopharmaceuticals, has products that compete in the pain management space, overlapping with Scilex's interests.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, through its extensive portfolio of medicines, competes in various therapeutic areas including pain management, directly challenging Scilex.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb offers a range of prescription medicines across several therapeutic areas, including pain, competing with Scilex's product offerings.

About

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Show more...
CEO
Dr. Henry H. Ji Ph.D.
Employees
115
Country
US
ISIN
US80880W2052

Listings

XNAS
US
SCLX
XNAS
US
SCLXW
F
DE
D8B0.F
BOATS
BOATS
SCLX.BOATS

0 Comments

Share your thoughts

FAQ

What is Scilex Company stock price today?▼
The current price of SCLX is $7.44 USD — it has increased by +7.67% in the past 24 hours. Watch Scilex Company stock price performance more closely on the chart.
What is Scilex Company stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Scilex Company stocks are traded under the ticker SCLX.
Is Scilex Company stock price growing?▼
SCLX stock has risen by +16.07% compared to the previous week, the month change is a -11.64% fall, over the last year Scilex Company has showed a +2,782.6% increase.
When is the next Scilex Company earnings date?▼
Scilex Company is going to release the next earnings report on June 03, 2026.
What were Scilex Company earnings last quarter?▼
SCLX earnings for the last quarter are -0.47 USD per share, whereas the estimation was -0.47 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Scilex Company revenue for the last year?▼
Scilex Company revenue for the last year amounts to 56.59M USD.
What is Scilex Company net income for the last year?▼
SCLX net income for the last year is -72.81M USD.
How many employees does Scilex Company have?▼
As of April 05, 2026, the company has 115 employees.
In which sector is Scilex Company located?▼
Scilex Company operates in the Health Care sector.
When did Scilex Company complete a stock split?▼
The last stock split for Scilex Company was on April 15, 2025 with a ratio of 1:35.
Where is Scilex Company headquartered?▼
Scilex Company is headquartered in Palo Alto, US.